Mark Colgin, Ph.D., age 42, was appointed Chief Scientific Officer in February 2009. He joined the Company in September 2000 as Director of Recombinant Technology and was promoted to Chief Scientist in January 2003.
Prior to joining the Company, his research focused on characterization and artificial synthesis of spider silk proteins, regulation of gene expression, neurovirology, and gene delivery systems. Dr. Colgin holds a B.S. in Biochemistry and a Ph.D. in Molecular Biology from the University of Wyoming.
Biography extracted from Riot DEF 14A filed 2010-10-22 View cached copy (2026-09-27)Live source ↗
Roles
Contiguous filings for the same role are collapsed into a single tenure span. Click a row to see the underlying filings.
| Company | Role | Tenure | Filings |
|---|---|---|---|
| Riot | Chief Scientific Officer | 2009-02 → present (17y 9mo) | 3 |
Show 3 underlying filings | |||
Compensation
| Year | Role as filed | Salary | Option awards | Incentive | Other | Total | Source |
|---|---|---|---|---|---|---|---|
| 2009 | Chief Scientific Officer | $146.9K | $54.8K | $23.0K | $11.4K | $236.1K | View cached copy (2026-09-27)Live source ↗ |
| 2008 | Chief Scientific Officer | $125.0K | — | $26.6K | $12.4K | $164.0K | View cached copy (2026-09-27)Live source ↗ |
| 2007 | Chief Scientific Officer | $105.0K | — | $60.0K | $12.4K | $177.4K | View cached copy (2026-09-27)Live source ↗ |
As reported in the company's DEF 14A Summary Compensation Table (SEC Reg S-K Item 402(c)). Stock and option awards are grant-date fair values — what the award was worth on the day it was granted, not cash received and not what it is worth now. Every row here reconciles: its columns add up to the total the filing printed.
Insider transactions
Totals for this person
| Bucket | Invested (shares) | Invested (USD) | Divested (shares) | Divested (USD) | Net direction | Txns | Invested @ last price | Divested @ last price |
|---|---|---|---|---|---|---|---|---|
| All time | 60,000 | $0 | - | $0 | Flat | 2 | $768.6K | $0 |
| 2011 | 10,000 | $0 | - | $0 | Flat | 1 | $128.1K | $0 |
| 2010 | 50,000 | $0 | - | $0 | Flat | 1 | $640.5K | $0 |
| 2010-Q1 | 50,000 | $0 | - | $0 | Flat | 1 | $640.5K | $0 |
| 2011-Q1 | 10,000 | $0 | - | $0 | Flat | 1 | $128.1K | $0 |
Invested = shares acquired (buys, grants, option exercises) — insider adding to the position. Divested = shares reduced (sells, dispositions, tax-withholding) — cash flowing TO the insider. Net direction shows which side wins on dollar terms in each bucket. % of holder's stake not yet computed (pending Form 3/4 holdings ingest). See methodology. The two @ last price columns restate the same share counts at the most recent share price we read (close of 2026-10-30); they are a valuation, not a cash flow, and they move every day the market does.
All transactions
| Date | Company | Kind | Shares | Amount (USD) | Value @ last price |
|---|---|---|---|---|---|
| 2011-01-05 | Riot | Grant / award / vesting · Stock Option (Right to Buy) | 10,000 | - | $128.1K |
| 2010-01-19 | Riot | Grant / award / vesting · Option -Right to Buy | 50,000 | - | $640.5K |